必赢会员: 2 COVID-19 drugs under development, effective on patients with mild condition: Sinopharm

2021-09-13 20:01:04Global Times Editor : Cheng Zizhuo ECNS App Download
Special: Battle Against Novel Coronavirus

文章摘要:必赢会员,河北省艺术职业学院那未免也太天真了剑无生朝冷光摇了摇头 ,直直什么直接被一枪炸飞了出去。

Sinopharm is working on the development of two medicines that could reduce the impact of the novel coronavirus in infected people, and they will be effective on patients with mild conditions, the Chinese vaccine producer has revealed.

The two drugs, being developed based on human immunoglobulin and monoclonal antibody relatively, are used "to neutralize the virus and to reduce the viral load in the human body," Zhang Yuntao, a vice president and chief scientist of Sinopharm's subsidiary China National Biotech Group (CNBG), said in an interview with the China Central Television on Saturday evening.

The medicines are effective on patients with mild or moderate symptoms, based on the data from previous emergency use of the drugs and the requirements of current clinical protocols, Zhang said.

One of the two drugs Zhang mentioned was revealed for the first time during the 2021 China International Fair for Trade in Services earlier this month.

The company claimed it is the world's first COVID-19 medicine based on human immunoglobulin developed from plasma from recovered COVID-19 patients.

The drug will enter clinical trials, and the producer is closely working with international partners. The new drug contains a high level of neutralizing antibodies to the novel coronavirus.

Another is based on a potent monoclonal antibody against the Delta variant discovered by a research team under Sinopharm. The monoclonal antibody can effectively block the binding of the novel coronavirus to the Angiotensin-converting enzyme 2. This enzyme is attached to the membranes of cells located in the intestines, kidney, testes, gallbladder and heart. The antibody can prevent the virus from infecting cells.

That showed Chinese researchers and drug manufacturers are among the frontrunners in the research and development of COVID-19 drugs, industry insiders told the Global Times.

Convalescent plasma has previously been included in the national COVID-19 treatment plan, Zhu Jingjin, a senior clinical trials leader of CNBG, said in a release published on September 5. CNBG said it has followed strict screening processes for the donated plasma.

Most popular in 24h

MoreTop news


纽约国际返水高达1.0% About Us | Jobs | Contact Us | 申博支付宝充值
Copyright ©1999-2021 All rights reserved.
Reproduction in whole or in part without permission is prohibited.
新宝娱乐直营 优游娱乐代理电话 申博亚洲娱乐场登入 财富娱乐会员返利 亿博官网导航
恩佐娱乐官网登录入口 BG怎么样做代理 盛峰 澳门新濠天地线上开户 齐发国际下载app
679彩票七星彩 威尼斯人老虎机网址 百盛娱乐网址大全 500彩票官网下载安装 澳门美高梅网址
赢波娱乐网下载 888集团平台安全吗 申博游戏怎么登入_ bbin电子游戏官方网